Comparison of two polymorphisms of the interleukin-1 gene family: Interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis

Critical Care Medicine

Volumn 27, Issue 7, 1999, Pages 1330-1334

  Fang, Xiang Ming ^a   Schröder, Stefan ^a   Hoeft, Andreas ^a   Stüber, Frank ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Cytokines; Gene polymorphism; Interleukin 1 ; Interleukin 1ra; Outcome; Sepsis; Susceptibility; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; LYMPHOTOXIN;

ARTICLE; DISEASE PREDISPOSITION; FEMALE; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEPSIS; TANDEM REPEAT;

CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERMANY; HUMANS; INTERLEUKIN-1; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-1; SEPSIS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0012382804     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199907000-00024     Document Type: Article

References (28)

1. American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovation therapies in sepsis. Crit Care Med 1992; 20:864-874
2. Tarlow JK, Blakemore AI, Lennard A, et al: Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91:403-404
3. Stüber F, Petersen M, Bokelmann F, et al: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996; 24:381-384
4. Pociot F, Molvig J, Wogensen L, et al: A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22:396-402
5. Jongeneel CV, Briant L, Udalova IA, et al: Extensive genetic polymorphism in the human tumor necrosis factor region and relation to extended HLA haplotypes. Proc Natl Acad Sci USA 1991; 88:9717-9721
6. Mansfield JC, Holden H, Tarlow JK, et al: Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994; 106:637-642
7. Clay FE, Cork MJ, Tarlow JK, et al: Interleukin 1 receptor antagonist gene polymorphism association with lichen sclerosus. Hum Genet 1994; 94:407-410
8. Cork MJ, Tarlow JK, Clay FE, et al: An allele of the interleukin-1 receptor antagonist as a genetic severity factor in alopecia areata. J Invest Dermatol 1995; 104:15S-16S
9. Goris RJ, te Boekhorst TP, Nuytinck JK, et al: Multiple-organ failure. Generalized autodestructive inflammation? Arch Surg 1985; 120:1109-1115
10. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning. A Laboratory Manual. Second Edition. New York, Cold Spring Harbor Laboratory Press, 1989, pp 14-21
11. Goldman M, Velu T: Interleukin-10 and its implications for immunopathology. Adv Nephrol Necker Hosp 1995; 24:79-90
12. Rogy MA, Auffenberg T, Espat NJ, et al: Human tumor necrosis factor receptor (p55) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses. J Exp Med 1995; 181:2289-2293
13. van der Poll T, Marchant A, Buurman WA, et al: Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol 1995; 155:5397-5401
14. de Bont ES, de Leij LH, Okken A, et al: Increased plasma concentrations of interleukin-1 receptor antagonist in neonatal sepsis. Pediatr Res 1995; 37:626-629
15. McCall CE, Grosso-Wilmoth LM, LaRue K, et al: Tolerance to endotoxin-induced expression of the interleukin-1 beta gene in blood neutrophils of humans with the sepsis syndrome. J Clin Invest 1993; 91:853-861
16. Fisher CJ Jr, Opal SM, Lowry SF, et al: Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis. J Crit Care 1994; 9:159-168
17. Gardlund B, Sjolin J, Nilsson A, et al: Plasma levels of cytokines in primary septic shock in humans: Correlation with disease severity. J Infect Dis 1995; 172:296-301
18. Goldie AS, Fearon KC, Ross JA, et al: Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 1995; 274:172-177
19. Hirsch E, Irikura VM, Paul SM, et al: Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci U S A 1996; 93:11008-11013
20. Ertel W, Kremer JP, Kenney J, et al: Down-regulation of proinflammatory cytokine release in whole blood from septic patients. Blood 1995; 85:1341-1347
21. McDowell TL, Symons JA, Ploski R, et al: A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 1995; 38:221-228
22. Harris MC, Costarino AT Jr, Sullivan JS, et al: Cytokine elevations in critically ill infants with sepsis and necrotizing enterocolitis. J Pediatr 1994; 124:105-111
23. van Deuren M: Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections. Eur J Clin Microbiol Infect Dis 1994; 13(Suppl 1):S12-16
24. Opal SM, Fisher CJ Jr, Dhainaut JF, et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25:1115-1124
25. Mancilla J, Garcia P, Dinarello CA: The interleukin-1 receptor antagonist can either reduce or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats. Infect Immun 1993; 61:926-932
26. Danis VA, Millington M, Hyland VJ, et al: Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99:303-310
27. Mandrup-Poulsen T, Pociot F, Molvig J, et al: Monokine antagonism is reduced in patients with IDDM. Diabetes 1994; 43:1242-1247
28. Stüber F, Udalova IA, Book M, et al: 308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 1996; 46:42-50